⌘K

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights
Resources
Pathways

Company

Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

Insights & Research

Latest updates on fibrosis research, biomarkers, and drug development trends.

Knocking on TGF-β's Gate: Why Integrin Inhibitors Are Back in the Spotlight

Exploring the latest developments in anti-fibrotic strategies targeting tissue-specific TGF-β activation via αvβ6/αvβ1 integrins.

Essential Guide to HFpEF Cardiac Fibrosis Models: TAC, AngII, ISO, Multi‑hit Selection

Effective in MI models, failed in HFpEF trials. The reason? Wrong model. Learn how to select the right HFpEF model (TAC, AngII, Multi-hit) targeting diastolic dysfunction and fibrosis, with E/e' echocardiography and Azan staining correlation analysis.

The Pitfall of Drug Discovery: 'No Reproducibility' in Preclinical Studies? Analysis of Failure Causes and 3 Re-evaluation Strategies

For researchers facing 'no reproducibility' or 'unexpected negative data' in preclinical studies. We explain failure causes from mismatch of model selection and evaluation systems, and introduce 3 re-evaluation strategies: STAM model, AI pathology, and PRO-C3.

The Key to Translational Research: Can You Measure it in Mice? Visualization Strategy for Fibrosis Biomarkers (FibroScan/PRO-C3)

'It worked in mice, but not in humans.' The key to crossing this valley of death is to evaluate with the same 'measure' as clinical trials. We explain how to utilize non-invasive biomarkers like FibroScan (CAP/VCTE), PRO-C3, and ELF score.

Beyond Animal Testing: The Promise and Perils of Organ-on-a-Chip in Fibrosis Research

Following the FDA Modernization Act 2.0, interest in Organ-on-a-Chip (MPS) is skyrocketing. We explore its potential to replace animal models in fibrosis research, its current limitations, and the pragmatic 'Hybrid Strategy'.

MASH / MASLD Therapeutics Landscape 2025: Pipeline & Market Analysis

Discover the 2025 MASH/MASLD drug development landscape. A comprehensive analysis of GSK, Roche, and Novo Nordisk mega-deals, FGF21 analog pipelines, and interactive industry realignment maps for pharma professionals.

IPF Development Map 2025: Approvals and Discontinuations

Analysis of the latest trends in the IPF field in 2025. Visualizing a year of contrasts with Boehringer Ingelheim's first new approval in over a decade, United Therapeutics' Phase 3 success, and Pliant's discontinuation.

How to Choose a Fibrosis CRO: The 2025 Guide to Preclinical Outsourcing Costs, Checklists & Strategy

Looking for a fibrosis CRO? This guide covers the key cost drivers of preclinical fibrosis studies, a 3-point quality checklist for CRO selection, standard timelines, and why specialized fibrosis CROs outperform generalists in delivering reproducible, IND-ready data.

Comprehensive Analysis of MASH Drug Development: Comparing Clinical and Preclinical Data and Future Prospects

An in-depth guide to the forefront of MASH therapeutics, drastically shifting since the 2024 approval of Resmetirom. We compare Phase 2/3 clinical data with preclinical GAN DIO-MASH models, detailing the potential and correlative mechanisms of next-generation drugs like Semaglutide, Lanifibranor, and Efruxifermin, along with future prospects for Lean MASH.

IPF Treatment Landscape 2026: Post-Nerandomilast Era, Treprostinil, and Disease-Modifying Candidates

Updated for 2026. Comprehensive analysis of the IPF pipeline — nerandomilast approval, inhaled treprostinil Phase 3 success, and next-gen disease-modifying drugs (ENV-101, buloxibutid, rentosertib) showing FVC improvement. Clinical data with preclinical evidence.

Precision in Pulmonary Fibrosis Models: Mastering Bleomycin Delivery & Study Design

Overcoming challenges in the Bleomycin IPF model. How Micro-Sprayer® technology and therapeutic dosing designs improve clinical predictability in preclinical trials.

IPF's Next Frontrunner Nerandomilast: How PDE4B Inhibition Rewrites the Standard of Care

Ofev/Esbriet only slow progression. Nerandomilast (Jascayd) showed add-on efficacy and won FDA approval in 2025. We decode the precision molecular design of PDE4B selectivity and the FIBRONEER-IPF data.